Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia 3Recurrence 2Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Hairy Cell 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 358Cyclophosphamide 241Azacitidine 213fludarabine phosphate 199venetoclax 198fludarabine 196Busulfan 148Decitabine 132Mycophenolic Acid 123Whole-Body Irradiation 122Peripheral Blood Stem Cell Transplantation 118Tacrolimus 115Granulocyte Colony-Stimulating Factor 104Idarubicin 100Filgrastim 100Melphalan 89Cyclosporine 89Methotrexate 83Daunorubicin 76Antilymphocyte Serum 75Etoposide 73Mitoxantrone 67Clofarabine 67Gemtuzumab 59Stem Cell Transplantation 55Thiotepa 51Cladribine 46Injections 45Specimen Handling 44thymoglobulin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Acute × Biological Therapy × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡